Top-News
Pharmazeutika USA

Amarantus BioScience Inc. News

Aktie
WKN:  A14UX2 ISIN:  US02300U2050 US-Symbol:  AMBS
0,0001 $
+0,00 $
0,00%
07.05.24 17:42:30
Handeln Depot/Watchlist
Aktienanzahl *
68,27 Mio.
Marktkapitalisierung *
6,28 Tsd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 18.08.2022

Amarantus BioScience Inc. News

27.04.22 - ACCESSWIRE
Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities
Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto ...
24.03.20 - PR Newswire
Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits
Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-​of-Care Screening and Confirmatory ...
25.10.19 - PR Newswire
Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings
Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings Portfolio includes treatments for Alzheimer's disease, ADHD, Parkinson's ...
11.01.19 - PR Newswire
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries PR Newswire
11.01.19 - PR Newswire
Amarantus gibt Partnerschaft mit IDEA Pharma zur Kommerzialisierung von Tochtergesellschaften bekannt
Amarantus gibt Partnerschaft mit IDEA Pharma zur Kommerzialisierung von Tochtergesellschaften bekannt PR Newswire
11.01.19 - PR Newswire
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries PR Newswire
01.12.17 - PR Newswire
Amarantus Provides Comprehensive Corporate Update
Amarantus Provides Comprehensive Corporate Update PR Newswire
17.11.17 - PR Newswire
Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants
Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants PR Newswire
27.09.17 - PR Newswire
Avant Diagnostics' Newly Appointed President & CEO Philippe Goix Delivered an Address to Shareholders
Avant Diagnostics' Newly Appointed President & CEO Philippe Goix Delivered an Address to Shareholders PR Newswire
18.07.17 - PR Newswire
Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+
Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in ...
12.07.17 - PR Newswire
Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform
Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform PR Newswire
17.04.17 - PR Newswire
Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology PR Newswire
05.04.17 - PR Newswire
Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.
Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc. PR Newswire
27.02.17 - PR Newswire
Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.
Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc. PR Newswire
10.02.17 - PR Newswire
Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld
Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld PR Newswire
08.08.16 - PR Newswire
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-​Threatening Pediatric Severe Burns ESS reduces mortality and ...
07.06.16 - PR Newswire
Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville Amarantus-​sponsored training for Phase 2 severe ...
03.06.16 - PR Newswire
Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results
Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results PR Newswire
31.05.16 - PR Newswire
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel ...
27.05.16 - PR Newswire
Amarantus Announces Upcoming Investor Presentations
Amarantus Announces Upcoming Investor Presentations PR Newswire

Newssuche

Videos

08:55 Uhr
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »